Clinical trial
RC48-ADC in Combination With Envolizumab for the First-line Treatment of Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2: A Prospective, Single-arm Phase II Trial.
NCT05417230 is registered in ClinicalTrials.gov with Jiangsu Cancer Institute & Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- RC48-ADC in Combination With Envolizumab for the First-line Treatment of Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2: A Prospective, Single-arm Phase II Trial.
- Lead sponsor
- Jiangsu Cancer Institute & Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 31, 2022
- Completion date
- August 31, 2025
- Enrollment
- 29 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
biliary tract cancer